|
CANMuc
|
The population is composed of individuals with a diagnosis of moderate-to-severe asthma confirmed by a respiratory physician, and/or a history of objective test evidence or a specialist’s past confirmation.
-
Minimum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Quebec city, Montreal, Ottawa, London, Sherbrooke, Hamilton, Vancouver
-
Ethnic Origin
-
-
Health Status
-
- Inclusion criteria:
* Respiratory physician–confirmed diagnosis of moderate-to-severe asthma (GINA Step 4 & Step 5).
* Individuals with historical objective evidence of asthma and/or specialist/respirologist confirmation (post-bronchodilator reversibility and/or methacholine bronchoprovocation test PC20 < 8 mg/mL).
Exclusion criteria:
* Individuals who have a history of heart attack or hospitalization for other heart problems, stroke, aortic or cerebral aneurysm, detached retina, or eye surgery within the previous 6 months of recruitment.
* Individuals with memory, cognitive, or psychiatric limitations that may prevent optimal participation.
* Individuals with an active or current history of other pulmonary disorders (e.g., pulmonary embolism, pulmonary hypertension, lung cancer) or who are suspected to have ciliary dyskinesia.
-
Other Criteria
-
Exclusion criteria:
* Individuals who cannot perform spirometry.
* Individuals who cannot be involved in another interventional clinical trial.
* Pregnant or breastfeeding women.
* Individuals who are current smokers (including marijuana or vaping), have a smoking history of more than 10 pack-years (one pack per day for over 10 years), or have smoked within the last 6 months.
* Exacerbation within 4 weeks of recruitment.
* Preterm birth (less than 36 weeks gestation) or perinatal complications.
* Individuals who are currently using mucolytic medications (e.g., inhaled hypertonic saline, inhaled DNase, or inhaled N-acetyl-cysteine).
* Individuals who are treated with current biologic therapy: anti-IgE mAb within 130 days, anti-IL-4/4R, IL-5/5R, IL-13, or TSLP within 2 months or 5 half-lives whichever is longer prior to visit 1.
-
Sources of recruitment
-
-
Specific Population
-
-
Supplementary Information
-
Participants are recruited through the CANMuc recruiting sites located across six Canadian academic health centres:
* McMaster University / St. Joe’s Healthcare Hamilton (Hamilton, ON)
* Western University / St. Joseph’s Healthcare London (London, ON)
* University of British Columbia / St. Paul’s Hospital (Vancouver, BC)
* Université de Sherbrooke / Centre hospitalier universitaire de Sherbrooke (CHUS) (Sherbrooke, QC)
* Université Laval / Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) (Québec City, QC)
* McGill University / McGill University Health Centre (MUHC) (Montréal, QC)
-
Number of Participants
-
100
-
Number of Participants with Biological Samples
-
100
CANMuc - Asthma Group
|
Information is collected on demographics and medical history, age, sex, identified gender, ethnicity, smoking status, atopy, smoking history, parental history, sinusitis, comorbidities and concomitant medications.
Information is collected on asthma control, respiratory health status, COPD symptoms, cough-related quality of life, breathlessness, autoimmune conditions, and cough severity through the Asthma Control Questionnaire (ACQ-5), St. George’s Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), Cough and Sputum Assessment Questionnaire (CASA-Q), modified Medical Research Council Dyspnea Scale (mMRC), Autoimmune Questionnaire, McMaster Cough Severity Questionnaire (MCSQ), Leicester Cough Questionnaire (LCQ), and the Cough Severity Visual Analog Scale (VAS).
Pre- and post-bronchodilator spirometry, pre- and post-bronchodilator oscillometry (at specified sites), and a 6-minute walk test are performed.
Urine is collected for females of child-bearing potential (less than 50 years) and who are postmenopausal for less than one year.
Induced sputum and blood are collected.
Post-bronchodilator high-resolution computed tomography (HRCT) of the chest for residual volume (RV) and total lung capacity (TLC), as well as post-bronchodilator ^129Xe ventilation and ^1H MRI (only at specified sites and only in participants without contraindications) are performed. Fractional exhaled nitric oxide (FeNO) is also measured as part of the lung function assessment.
24-hour cough is monitored through the VitaloJAK portable cough monitoring device.
-
Start Date
-
2025-01
-
Data sources
-
-
Questionnaires
-
Physical measures
-
Biosamples
-
Other : VitaloJAK
-
Data sources - Biosamples
-
-
Blood
-
Urine
-
Other : Induced sputum
-
Files
-
CANMuc - Asthma Group - Visit 1
|
|
CLOUD
|
The population is composed of adults who are able to participate in Vancouver (British Columbia), Edmonton (Alberta), Hamilton (Ontario), Ottawa (Ontario), or Sherbrooke (Quebec).
-
Minimum age
-
19
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Vancouver, Edmonton, Hamilton, Ottawa, Sherbrooke
-
Ethnic Origin
-
-
Health Status
-
-
Other Criteria
-
Non-smoking and non-ENDS using participants will be recruited to match the age and sex distribution of the
ENDS and cigarette smoking groups.
-
Sources of recruitment
-
-
General Population
-
-
Supplementary Information
-
Participants are recruited through social media, educational initiatives in schools, awareness programs, the study website, and online health research platforms like REACH BC.
-
Number of Participants
-
400
-
Number of Participants with Biological Samples
-
400
-
Supplementary Information about selection criteria
-
**This population includes:**
* 100 ENDS-only users
* 100 combustible cigarette-only users
* 100 dual e-cigarette and combustible cigarette users
* 100 non-smoking and non-e-cigarette users
CLOUD - Adults
|
Demographic, exposure, and medical history, along with vaping habits (device type, frequency, e-liquid composition, and flavorings), are recorded. Vaping dependence is assessed using the modified Fagerström test.Validated respiratory symptom questionnaires include the St. George’s Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), modified Medical Research Council dyspnea scale, International Physical Activity Questionnaire (short form), and McMaster Cough Severity Questionnaire.
An online survey captures respiratory exacerbations and work/school absences. Pulmonary function tests are conducted, along with oscillometry using the tremoFlo™ C-100 system.
Cardiopulmonary Exercise Testing (CPET) is performed to assess cardiac, metabolic, and ventilatory parameters. A chest CT scan and pulmonary MRI are completed, with qualitative image analysis for lung abnormalities.
Blood and lung biospecimens are collected. An optional bronchoscopy allows collection of oral washes, airway epithelial brushings, and bronchoalveolar lavage.
-
Start Date
-
2025-05
-
End Date
-
2027-05
-
Data sources
-
-
Questionnaires
-
Physical measures
-
Biosamples
-
Other : Magnetic Resonance Imaging (MRI), CT Scan, Bronchoscopy, Oscillometry test
-
Data sources - Biosamples
-
-
Blood
-
Tissues : Bronchoscopy samples
-
Files
-
CLOUD - Adults - Visit 1
|